The peptide somatostatin (SRIF) is widely distributed throughout the brain and periphery, where it exerts a variety of hormonal and neuronal actions (Patel, 1999) . In the temporal cortex, an area involved in cognitive functions, SRIF plays an important role as a neurotransmitter and has been implicated in learning and memory processes (Dournaud et al., 1996) . Its biological actions are mediated by receptors belonging to the G-protein-coupled receptor (GPCR) family. Five SRIF receptor subtypes, termed somatostatin receptor (sst) 1-sst5, have been identified in mammals, with two splice variants of sst2 in mouse and rat, sst2A and sst2B (Hoyer et al., 1995) . Sst1-sst4 are highly expressed in the cortex whereas sst5 receptor immunoreactivity is only sparsely present in neuronal perikarya and proximal dendrites limited to the rostral part of the brain (Stroh et al., 2000) . Ssts elicit their cellular responses via G-protein-linked-modulation of multiple second-messenger systems including adenylyl cyclase (AC), Ca 2ϩ and K ϩ ion channels, Na ϩ /H ϩ antiporter, guanylate cyclase, phospholipase C, phospholipase A 2 , MAP kinase, and serine, threonine and phosphotyrosyl protein phosphatase (Patel, 1999) .
Over the years, considerable evidence has accumulated pointing toward a close relationship between SRIF, Alzheimer's disease (AD) and amyloid-beta peptide (A␤). Among the numerous neuropeptides produced in intrinsic cortical and hippocampal neurons, SRIF has been found to be the most consistently reduced in the brain and cerebrospinal fluid of AD patients (Davies et al., 1980; Beal et al., 1986; Nemeroff et al., 1992; Bissette et al., 1998; BurgosRamos et al., 2008) . SRIF receptors are also markedly depleted in the AD brain (Beal et al., 1985) , there being subtype-selective alterations in cortical areas (Kumar, 2005) . AD is characterized clinically by progressive dementia and, histopathologically, by the presence of extracellular deposits of amyloid fibrils in the core of senile plaques, intracellular neurofibrillar tangles and neuronal cell loss (Braak and Braak, 1991; Selkoe, 2001) . One of the principal components of senile plaques is A␤, which is considered to be involved in the pathogenesis of AD (Hsiao et al., 1996; Selkoe, 2001) . Our group has recently shown that chronic A␤ (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) infusion, an animal model of AD, decreases sst density and expression in the rat frontoparietal cortex (Hervás-Aguilar et al., 2005) and temporal cortex , an effect accompanied by decreased receptor functionality.
Minocycline is a semisynthetic second-generation tetracycline which is used clinically as an antimicrobial agent. In addition to its efficacy in the treatment of multidrugresistant infections, this antibiotic has a good clinical safety record and is a highly lipophilic molecule which easily penetrates the blood-brain barrier (Aronson, 1980) . In recent years, it has been shown to exhibit powerful antiinflammatory properties that are completely distinct from its antimicrobial action. As a result, minocycline has been shown to ameliorate disease severity in several animal models of neurological diseases, including stroke, amyotrophic lateral sclerosis, Huntington's disease and Parkinson's disease (Bantubungi et al., 2005) . A recent report demonstrated that minocycline inhibits A␤-induced neuronal death and glial activation in the rat hippocampus (Ryu et al., 2004) . Minocycline has also been reported to affect A␤ deposition and behavior in amyloid precursor protein transgenic mice and to improve cognition in young mice (Seabrook et al., 2006) . In addition, Hunter et al. (2004) , using an experimental model of AD in mice, have documented that minocycline reduces the magnitude of cholinergic fiber loss in the hippocampus and attenuates cognitive impairment. To date, however, it is unknown whether minocycline can protect the SRIF receptor-effector system from alterations present in the AD brain and after chronic A␤ infusion Hervás-Aguilar et al., 2005) . To address this issue, we examined the effects of minocycline on:
125 I-Tyr 11 -SRIF binding to SRIF receptors, sst1-sst4 protein expression, sst mRNA levels, phosphorylated and total cyclic AMP (cAMP) response element binding protein (CREB) content, basal and stimulated AC activity, SRIF-induced inhibition of AC activity and Gi␣1-Gi␣3 protein levels in the temporal cortex of control and A␤(25-35)-treated rats. In addition, since G protein-coupled receptor kinases (GRKs) play a key role in the regulation of GPCR function (Gainetdinov et al., 2004) and GRK alterations appear to be closely associated with very early accumulation of soluble A␤ peptide in the brain (Suo et al., 2004) , the protein content of the isoform GRK2 in the temporal cortex of control, minocycline-, A␤(25-35)-and minocycline plus A␤(25-35)-treated rats was also assessed.
EXPERIMENTAL PROCEDURES Reagents
Synthetic Tyr 11 -SRIF and SRIF-14 were purchased from Universal Biologicals Ltd. (Cambridge, UK); carrier-free Na 125 I (IMS 100 mCi/mL) was purchased from the Radiochemical Center (Perkin Elmer, Boston, MA, USA); bacitracin, bovine serum albumin (BSA), forskolin (FK), A␤(25-35), minocycline, phenylmethylsulfonyl fluoride (PMSF), guanosine triphosphate, 3-isobutyl-1-methylxantine (IBMX) and the specific antibody against total-CREB were purchased from Sigma (Madrid, Spain). TriReagent for RNA isolation was from Molecular Research Center (Cincinnati, OH, USA). DNase I RNase-free was purchased from Roche Applied Science (Indianapolis, IN, USA). Moloney murine leukemia virus reverse transcriptase (MMLV-RT) and other reagents for the reverse transcription reaction (RT) were obtained from Invitrogen Ltd. (Barcelona, Spain). Specific monoclonal antibodies to the ␣i1 (MAB 3075) or ␣i2 (MAB 3077) G protein subunits were obtained from Chemicon International (Temecula, CA, USA). The specific antisera against the ␣i3 G protein subunit (sc-262), the SRIF receptor subtypes sst1 (sc-11604), sst2 (sc-11606), sst3 (sc-11614) and sst4 (sc-11619), as well as the antibody to GRK2 (sc-13143) were obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). The specific antibody to phospho-CREB was purchased from Cell Signaling (Boston, MA, USA). Nitrocellulose membranes and the chemiluminescence Western blotting detection system were purchased from Amersham (Buckinghamshire, UK).
Experimental animals
The rats were treated according to the European Community laws for animal care and the experiment was approved by the Animal Care Committee of Alcalá University. All efforts were made to minimize animal suffering and to use only the number of animals deemed necessary to produce reliable scientific data. Forty male Wistar rats weighing 200 -250 g were used in this study. All animals received food and tap water ad libitum. Room temperature was kept at 22°C and a 12-h light/dark cycle was maintained. The A␤(25-35) peptide was dissolved in 1% acetic acid according to the manufacturer's instructions and was incubated at 37°C the day before its administration. On the day of surgery, a cannula attached to an osmotic minipump (Alzet) was implanted in the rat left lateral cerebral ventricle, as previously described (Nitta et al., 1994) and A␤(25-35) was continuously infused at a dose of 300 pmol/day for 14 days (Nitta et al., 1994) . Another group of male Wistar rats was injected with minocycline (45 mg/kg body weight) i.p. twice on the first day of treatment (Yrjänheikki et al., 1999) . On the following day and during 14 days, A␤(25-35) was administered i.c.v. via an osmotic minipump connected to a cannula implanted in the left lateral ventricle (300 pmol/day). Minocycline (22.5 mg/ kg, i.p.) was injected once again the last 2 days of the A␤(25-35) infusion. A third group of rats received a similar treatment with minocycline in the absence of A␤(25-35) infusion. Control animals received equivalent volumes of vehicle. All animals were decapitated 14 days after the first injection. The brains were quickly removed from the skull and the temporal cortex was immediately dissected on ice.
Membrane preparation
The temporal cortex was homogenized in 10 mM Hepes-KOH buffer, pH 7.6 (10% wt/vol) with a Brinkmann polytron homogenizer (setting 5, 15 s). The homogenate was spun at 600ϫg for 5 min at 4°C, and the supernatant was centrifuged at 48,000ϫg for 30 min at 4°C. The resulting pellet was suspended in 10 mM Hepes-KOH, pH 7.6 (10% w/v) and then centrifuged as before. The resultant pellet was resuspended in 50 mM Tris-HCl buffer, pH 7.5. Samples were immediately aliquoted and stored at Ϫ80°C until the day of assay.
Preparation of cell lysate
A small sample of the temporal cortex from the different experimental animals was isolated and suspended in 500 l of lysis buffer (20 mM Hepes, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 5% glycerol, 10 mM pyrophosphate, 1 mM NaVO 3 , 1 mM PMSF, 5 g/mL aprotinin, 5 g/mL STI and leupeptin, pH 7.5). The samples were sonicated for 5 s, allowed to incubate on ice for 30 min with agitation, and then cleared by centrifugation in a tabletop centrifuge at 15,000ϫg at 4°C for 15 min. The lysate was subsequently aliquoted and stored at Ϫ20°C until the day of assay. One aliquot was used to determine protein concentration by the Lowry method (Lowry et al., 1951) .
Binding assay
Tyr 11 -SRIF was radioiodinated by the chloramine-T method according to Greenwood et al. (1963) . The tracer was purified in a Sephadex G-25 fine column (1ϫ100 cm) equilibrated with 0.1 M acetic acid containing BSA 0.1% (w/v). The specific activity of the purified labeled peptide was about 600 Ci/mmol. Membranes from the rat temporal cortex were prepared as previously described by Reubi et al. (1981) . The protein concentration was assayed by the Lowry method, with BSA as a standard. Specific SRIF binding was measured according to the modified method of Czernik and Petrack (1983) . Briefly, the membranes (0.15 mg protein/mL) were incubated in 250 L of a medium containing 50 mM Tris-HCl buffer (pH 7.5), 5 mM MgCl 2 , 0.2% (w/v) BSA and 0.1 mg/mL bacitracin with 250 pM of 125 I-Tyr 11 -SRIF, either in the absence or presence of 0.01-10 nM unlabeled SRIF. After one 60-min incubation at 30°C, bound and free ligand were separated by centrifugation at 11,000ϫg for 2 min and the radioactivity in the resultant pellet was measured. Nonspecific binding was obtained from the amount of radioactivity bound in the presence of 10 Ϫ7 M SRIF and represented about 20% of the binding observed in the absence of unlabeled peptide. This nonspecific component was subtracted from the total bound radioactivity in order to obtain the corresponding specific binding.
AC assay
AC activity was measured as previously reported (Houslay et al., 1976) , with minor modifications. Briefly, membranes from the temporal cortex (0.06 mg/mL) were incubated with 1.5 mM ATP, 5 mM MgSO 4 , 10 M GTP, an ATP-regenerating system (7.5 mg/mL creatine phosphate and 1 mg/mL creatine kinase), 1 mM IBMX, 0.1 mM PMSF, 1 mg/mL bacitracin, 1 mM EDTA, and test substances (10 Ϫ4 M SRIF or 10 Ϫ5 M FK) in 0.1 mL of 0.025 M triethanolamine/HCl buffer, pH 7.4. After one 15-min incubation at 30°C, the reaction was stopped by heating the mixture for 3 min at 90°C. After cooling, 0.2 mL of an alumina slurry (0.75 g/mL in triethanolamine/HCl buffer, pH 7.4) was added and the suspension was centrifuged. The supernatant was taken for assay of cAMP by the method of Gilman (1970) .
RT and the polymerase chain reaction
Total RNA was isolated from the temporal cortex in guanidinium isothiocyanate, using a commercial kit (Tri Reagent). The total RNA samples were digested with DNase I, purified with phenolchloroform-isoamyl alcohol (1:1:0.02) and stored at Ϫ80°C until analysis. The RNA concentration and purity in the final preparation were spectrophotometrically quantified by measuring the absorbance at 260 and 280 nm (Ultrospec Plus UV/Vis Spectrophotometer, Pharmacia Biotech, Uppsala, Sweden). The RNA integrity was checked on a denaturing 1.5% agarose gel stained with ethidium bromide. Total RNA (1 g) was primed with Oligo(dT) 12-18 and incubated with MMLV-RT to synthesize cDNA. An RT reaction in the absence of MMLV-RT was performed as a control for genomic DNA contamination. The sst2 primers used for PCR amplification are shown in Table 1 . The following conditions were used: denaturation at 94°C for 1 min, annealing at 55°C for 30 s, and extension at 72°C for 90 s. ␤-Actin primers were added as an internal standard (Table 1) . Sst2 was coamplified with ␤-actin for 30 cycles, followed by a final extension at 72°C for 10 min. Following PCR, the samples were run on an agarose gel (with a density gradient of 2%-1.5%-1%) and the bands were visualized after staining with ethidium bromide.
Immunodetection of the ␣i subunits of G proteins, GRK2, phospho-CREB, total-CREB and sst1-sst4
The membranes and cell lysates were solubilized in SDS-sample buffer and the proteins (100 g) were then run on a 12% SDSpolyacrylamide gel. After separation, the proteins were transferred onto nitrocellulose membranes in a buffer containing 25 mM TrisHCl, pH 8.3, 192 mM glycine, 20% methanol and 0.05% SDS. The nitrocellulose membranes were then blocked with TTBS (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, and 0.05% Tween-20) containing 5% (w/v) non-fat dry milk for 1.5 h at 4°C. The nitrocellulose membranes were subsequently incubated with the corresponding antibodies: mouse anti-Gi␣1, anti-Gi␣2, or anti-GRK2 monoclonal antibodies (1:1000 dilution), rabbit anti-Gi␣3 polyclonal antibody (1:1000 dilution), rabbit anti-phospho-CREB or anti-CREB monoclonal antibody (1:1000 dilution) or goat anti-sst1, anti-sst2, antisst3 or anti-sst4 polyclonal antibody (1:1000 dilution) in TTBS overnight at 4°C. After incubation, three 5-min washes in TTBS containing 5% (w/v) non-fat dry milk were carried out. A goat, mouse or rabbit IgG-peroxidase conjugate (1:2000 dilution) in TTBS was then added to the membranes and incubated for 1 h at 4°C. After washing, the bound immunoreactive proteins were detected by a chemiluminescent (ECL) Western blotting detection system. Quantification of the bands was carried out by densitometric analysis using the Scion Image computer program (Scion Inc.).
Data analysis
The computer program LIGAND (Munson and Rodbard, 1980) was used to analyze the binding data. The use of this program enables models of receptors which best fit a given set of binding data to be selected. The same program was also used to present data in the form of Scatchard plots and to compute values for receptor affinity (Kd) and density (Bmax) that best fit the sets of binding data for each rat. Statistical comparisons of all data were carried out by one-way analysis of variance (ANOVA) and the Student-Newman-Keuls test. Means among groups were considered significantly different when the P values were less than 0.05. Each experiment was performed in duplicate.
RESULTS
Membranes from the temporal cortex of the different experimental groups bound [ 125 I-Tyr 11 ]-SRIF in a time-dependent manner, with a maximal specific binding at 30°C, 60 min, remaining stable thereafter until at least 120 min (data not shown). A 60-min incubation period was thus chosen to study the stoichiometry of the binding reaction. SRIF degradation by the membranes was also assessed in order to rule out the possibility of different SRIF degrading activities that could affect the interpretation of the results. All membrane preparations showed similar levels of SRIF degradation, with values varying by no more than 11.5%. SRIF competitively inhibited the specific binding of [ 125 ITyr 11 ]-SRIF to its membrane receptors in the rat temporal cortex of all the experimental animals ( Fig. 1, left panel) . The specific binding of the tracer in the A␤(25-35)-treated group, however, was significantly lower than that in the control group, in the absence or presence of SRIF. The corresponding equilibrium parameters for the SRIF receptors, shown in Table 2 , reveal that A␤(25-35) administration decreased the density and the dissociation constant of the SRIF receptors in the temporal cortex. Minocycline treatment prevented the A␤(25-35)-induced decrease in the SRIF receptor density, but exerted no effect on either parameter when administered alone to control rats (Table 2) .
To test which SRIF receptor subtypes were affected by these treatments, Western blot analyses of sst1-4 were performed in membranes from the rat temporal cortex. A significant decrease in sst2 protein levels was found in the A␤(25-35)-treated group, no significant differences being observed in either sst1, sst3 or sst4 protein content (Fig. 2) . Minocycline administration, however, abrogated the A␤(25-35)-induced decrease in sst2 protein expression, exerting no effect on this parameter when administered alone to rats treated with vehicle (Fig. 2) .
A functional cyclic AMP response element (CRE) has been identified within the second promoter of the rat sst2 gene (Kimura et al., 2001 ). Sst2 expression is known to be induced by cAMP (Kraus et al., 2000) . Classically, elevation of intracellular cAMP levels leads to protein kinase A (PKA) activation. The activated catalytic subunit of PKA enters the cell nucleus, where CREB is phosphorylated. Binding of phosphorylated cyclic AMP response element binding protein (p-CREB) to CRE then leads to enhanced gene transcription (Mayr and Montminy, 2001) . In view of this, we next sought to examine the levels of p-CREB and total CREB in order to gain further insight into the mechanism underlying the A␤(25-35)-induced decrease in SRIF binding and sst2 expression and its restoration by minocycline. We proposed that these treatments might be altering the rate of gene transcription by modifying the levels of the activated form of CREB. Western blot analysis revealed that whereas A␤(25-35) administration induces a significant decrease in both p-CREB and total CREB content in the rat temporal cortex, this effect is completely abrogated by minocycline pretreatment (Fig. 3) . Minocy- Equilibrium parameters for SRIF binding to membranes from the temporal cortex of control rats (nϭ5), rats treated with A␤(25-35) (300 pmol/day for 14 days) (nϭ5), rats treated with minocycline (45 mg/kg, i.p. twice on the first day and 22.5 mg/kg on days 13 and 14) and rats treated with minocycline (45 mg/kg, i.p. twice on the first day and 22.5 mg/kg on days 13 and 14) plus A␤(25-35) (300 pmol/day for 14 days) (nϭ5). Binding parameters were calculated from Scatchard plots by linear regression. Units for Kd are nM and units for Bmax are femtomoles of SRIF bound per mg of protein. The results represent the meanϮS.E.M. of five rats. Each experiment was performed in duplicate. * PϽ0.05, statistical comparison versus control.
Fig. 2. (A)
Autoradiographs derived from the immunoblots of the different sst subtypes (sst1-sst4) in membranes from the rat temporal cortex. Lane 1 corresponds to control rats (nϭ5), lane 2 to rats treated with A␤(25-35) (300 pmol/day for 14 days) (nϭ5), lane 3 to rats treated with minocycline (45 mg/kg, i.p. twice on the first day and 22.5 mg/kg on days 13 and 14) and lane 4 to rats treated with minocycline (45 mg/kg, i.p. twice on the first day and 22.5 mg/kg on days 13 and 14) plus A␤(25-35) (300 pmol/day for 14 days). The membrane proteins were resolved by SDS-PAGE as described in the Experimental Procedures section. Proteins were transferred to nitrocellulose membranes and immunodetection was carried out by using a goat anti-sst1, anti-sst2, anti-sst3 or anti-sst4 polyclonal antibody. Each experiment is representative of five others. An anti-␤ tubulin antibody was used to check for equal loading. (B) Densitometric analysis of the autoradiographs derived from the immunoblots of the sst2 subtype. The integrated optical densities are presented as a percent of the control value. Statistical comparison versus control: *** PϽ0.001.
cline alone significantly enhanced p-CREB protein levels in this brain area (Fig. 3) . Likewise, total CREB content was increased by minocycline, suggesting that the drug alters not only the degree of CREB phosphorylation but its synthesis as well.
To further investigate the protective effects of minocycline on sst2 protein expression, the mRNA levels of this receptor subtype were determined by RT-PCR. Chronic A␤(25-35) infusion led to a reduction in sst2 mRNA levels in the rat temporal cortex. Minocycline treatment alone to vehicle-injected rats led to a rise in sst2 mRNA levels and when administered to A␤(25-35)-infused rats, restored mRNA levels to control values (Fig. 4) .
On the other hand, different members of the GPCR family are known to desensitize and internalize upon phosphorylation by GRKs. Hence, there lies the possibility that the A␤(25-35)-induced decrease in sst2 protein content might be, at least partly, attributable to an increased rate of internalization of the receptor by GRK-mediated phosphorylation. To explore this alternative hypothesis, we analyzed GRK2 protein expression, the isoform most abundantly expressed in the cerebral cortex, by Western blotting using a subtype-specific monoclonal antibody. An enhanced expression of GRK2 was detected in animals infused chronically with A␤(25-35), as compared with GRK2 protein levels in control rats (Fig. 5) . Minocycline pre-treatment prevented the rise in GRK2 levels, whereas it exerted no effect on this parameter when administered to rats treated with vehicle (Fig. 5 ).
All SRIF receptor subtypes couple negatively to the effector AC, leading to a reduction in cAMP production. Thus, our next goal was to assess the functionality of the SRIF receptors. To this end, we measured the effects of A␤(25-35), minocycline and minocycline plus A␤(25-35) administration on basal and FK-stimulated AC activity, as Fig. 3. (A) Autoradiographs derived from the immunoblots of p-CREB and total CREB in cells extracts from the rat temporal cortex. Lane 1 corresponds to control rats (nϭ5), lane 2 to rats treated with A␤(25-35) (300 pmol/day) for 14 days (nϭ5), lane 3 to rats treated with minocycline (45 mg/kg, i.p. twice on the first day and 22.5 mg/kg on days 13 and 14) and lane 4 to rats treated with minocycline (45 mg/kg, i.p. twice on the first day and 22.5 mg/kg on days 13 and 14) plus A␤(25-35) (300 pmol/day for 14 days). The membrane proteins were resolved by SDS-PAGE as described in the Experimental Procedures section. Proteins were transferred to nitrocellulose membranes and immunodetection was carried out by using a rabbit anti-CREB and anti-p-CREB monoclonal antibody. Each experiment is representative of five others. An anti-␤ tubulin antibody was used to check for equal loading. Autoradiographs derived from the immunoblots of the GPCR kinase isoform GRK2 in membranes from the rat temporal cortex. Lane 1 corresponds to control rats (nϭ5), lane 2 to rats treated with A␤(25-35) (300 pmol/day for 14 days) (nϭ5), lane 3 to rats treated with minocycline (45 mg/kg, i.p. twice on the first day and 22.5 mg/kg on days 13 and 14) and lane 4 to rats treated with minocycline (45 mg/kg, i.p. twice on the first day and 22.5 mg/kg on days 13 and 14) plus A␤(25-35) (300 pmol/day for 14 days). The membrane proteins were resolved by SDS-PAGE as described in the Experimental Procedures section. Proteins were transferred to nitrocellulose membranes and the immunodetection was carried out by using a mouse anti-GRK2 monoclonal antibody. Each experiment is representative of five others. An anti-␤ tubulin antibody was used to check for equal loading. (B) Densitometric analysis of the autoradiographs derived from the immunoblots of GRK2 in the temporal cortex from the different experimental groups. The integrated optical densities for the different experimental groups are presented as a percent of the control value. Statistical comparison versus control: ** PϽ0.01.
well as the capacity of SRIF to inhibit these activities. As shown in Table 3 , no significant differences in either basal or FK-stimulated AC activity were found in temporal cortical membranes from the different experimental groups under analysis. Likewise, basal or FK-stimulated AC activity was inhibited by SRIF in all the experimental animals. In the A␤(25-35)-treated group, however, the capacity of SRIF to inhibit basal or FK-stimulated AC activity in these membranes was attenuated (Table 3) , an effect which was abolished by minocycline treatment (Table 3) .
It is well established that all three G proteins belonging to the Gi family, namely Gi␣1, Gi␣2, and Gi␣3, couple ssts to AC. Hence, this raises the question of whether the attenuated ability of SRIF to inhibit AC activity in the A␤(25-35)-treated rats might be a consequence of changes at the Gi level. To address this issue, Western blot analyses of the ␣i1, ␣i2 and ␣i3 subunits of Gi proteins were performed in temporal cortical membranes from control, A␤(25-35)-, minocycline-, and minocycline plus A␤(25-35)-treated rats. The results obtained demonstrate that neither A␤(25-35) nor minocycline alters the protein expression of any of the three ␣i subunits studied (Fig. 6 ).
DISCUSSION
The main finding here is that minocycline exerts a protective role against A␤(25-35)-induced impairment of the SRIF signaling pathway in the rat temporal cortex.
Chronic i.c.v infusion of A␤(25-35), located at the Cterminus of A␤(1-42), was used to partially reproduce AD in rats. The experimental conditions were selected according to previous studies demonstrating that they mimic some of the pathological processes in AD brain, including the cognitive deficits (Nitta et al., 1994) . This fragment is proposed to be the functional domain of A␤ responsible for its neurotoxic properties (Pike et al., 1993) . In the past, the presence of A␤(25-35) in vivo was controversial. Kubo et al. (2002) have provided evidence that insoluble A␤(1-40), present in the senile plaques characteristic of AD, can be racemized at Ser revealed the presence of both fragments in the AD brain but not in age-matched control brains (Kubo et al., 2002) .
After continuous A␤(25-35) infusion, a decrease in sst density was detected in the rat temporal cortex, consistent with data previously published by our group and found in the postmortem cerebral cortex of AD patients (Krantic et al., 1992) . The A␤(25-35)-induced reduction in the rat temporal cortex is partly due to a selective decrease in sst2 expression. Although the lower sst2 protein levels might be attributable to post- and ␣i3 subunits of Gi proteins in membranes from the rat temporal cortex. Upper panel: Lane 1 corresponds to control rats (nϭ5), lane 2 to rats treated with A␤(25-35) (300 pmol/day for 14 days) (nϭ5), lane 3 to rats treated with minocycline (45 mg/kg, i.p. twice on the first day and 22.5 mg/kg on days 13 and 14) and lane 4 to rats treated with minocycline (45 mg/kg, i.p. twice on the first day and 22.5 mg/kg on days 13 and 14) plus A␤(25-35) (300 pmol/day for 14 days). The membrane proteins were resolved by SDS-PAGE as described in the Experimental Procedures section. Proteins were transferred to nitrocellulose membranes and immunodetection was carried out by using a mouse anti-Gi␣1 or anti-Gi␣2 monoclonal antibody, or a rabbit antiGi␣3 polyclonal antibody. Each experiment is representative of five others. An anti-␤ tubulin antibody was used to check for equal loading. Data represent the meanϮS.E.M. of five rats. Lower panel: Densitometric analysis of the autoradiographs derived from the immunoblots of Gi proteins in the temporal cortex from the different experimental groups. The integrated optical densities for the different experimental groups are presented as a percent of the control value. translational modifications and/or alterations in protein stability, the fact that sst2 mRNA levels were also reduced after A␤(25-35) administration points toward a decreased rate of gene transcription. SstII is the main subtype expressed in the cerebral cortex and is a prototype of a receptor whose gene contains a CRE regulated by the transcription factor CREB (Kraus et al., 2000) . Phosphorylation of CREB on Ser-133 is required for the recruitment of the co-activator CBP and thus, for initiation of CREBdependent transcription (Mayr and Montminy, 2001 ). Here we show that A␤(25-35) treatment induces a reduction in p-CREB immunoreactivity in the temporal cortex, which could account for the lower sst2 mRNA levels. This finding is concordant with in vitro studies in which A␤(1-40) was shown to suppress CREB phosphorylation in cultured cortical neurons (Tong et al., 2001) . Notwithstanding, other transcription factors might also be involved. Kimura et al. (2001) reported that the rat sst2 promoter contains consensus motifs for transcription factors such as T3R, ER or NF-kappaB and that rat sst2 mRNA levels are up-regulated by chronic treatment with estrogen, suggesting that the CRE site partly mediates the promoter activity activated by estrogen.
Minocycline is a lipid-soluble tetracycline that easily crosses the blood-brain barrier (Aronson, 1980) and has been documented to exert an inhibitory effect on A␤ fibril formation and microglial activation (Seabrook et al., 2006) . The doses used in our experiments were selected according to a previous study carried out by Yrjänheikki et al. (1999) who showed that they exert neuroprotective effects in global brain ischemia. The changes in 125 I-Tyr 11 -SRIF binding and sst2 mRNA and protein content detected after A␤(25-35) infusion were abrogated by minocycline treatment. Minocycline administration to A␤(25-35)-infused rats also normalized p-CREB and total CREB levels. CREB phosphorylation is regulated by a variety of cellular signaling pathways involved in growth, development and differentiation. MAPK and ERK, for example, have been shown to activate CREB, reducing apoptosis in human neuroblastoma cells (Park and Cho, 2006) . In addition, the Akt signaling pathway modulates cell integrity and cell survival via activation of several substrates, including CREB (Chong et al., 2005) . Pi et al. (2004) have demonstrated that minocycline enhances Akt phosphorylation, triggered by phosphatidylinositol-3-kinase signaling, in cerebellar neurons. In view of these findings, it is feasible that minocycline might increase CREB phosphorylation in the temporal cortex via the Akt pathway, thereby leading to enhanced sst2 transcription, thus counteracting the effect of A␤(25-35) on sst2 expression.
Whereas multiple mechanisms contribute to the regulation of GPCRs, GRKs and arrestins play a key role. GRKs comprise a family of serine/threonine kinases that are uniquely able to associate with the agonist-occupied form of the receptor (Gainetdinov et al., 2004) . Signaling is terminated upon receptor phosphorylation and subsequent binding of arrestins, uncoupling the receptor from the Gprotein. GRKs can be divided into three subgroups based on sequence and functional criteria: GRK1 and 7, expressed almost exclusively in retina, GRK2 and 3, and GRK4-5 and 6, which are ubiquitously expressed (Gainetdinov et al., 2004 ). GRK2-6 are all found in the brain, suggesting an important role in neuronal signal transduction (Gainetdinov et al., 2004) . In our study, the decrease in sst2 protein levels in the temporal cortex of the A␤(25-35)-infused rats was associated with a significant enhancement of GRK2 immunoreactivity. The number of cell surface receptors is a function of the combined processes of insertion of newly synthesized receptors into the plasma membrane and internalization of these receptors. Therefore, an altered rate of internalization could contribute to the decrease in sst2 protein content. Tulipano et al. (2004) demonstrated that in HEK293 cells transfected with both GRK2 and sst2A, sst2A internalization was dependent on GRK2-mediated phosphorylation of serine and threonine residues present in the C-terminus of the receptor. Agonist-induced phosphorylation of sst3, however, was GRK2-independent whereas neither sst1 nor sst4 exhibited phosphorylation. Furthermore, overexpression of GRK2 markedly increased sst2A phosphorylation, facilitating the recruitment of ␤-arrestin-2 to the plasma membrane. Several studies support the hypothesis that alterations in GRK protein expression represent another means of regulating GRK activity (Rockman et al., 1996) . Hence, in our experimental model of AD, increased GRK2 protein levels could lead to increased sst2-GRK2 interaction and thereby, to an increased phosphorylation and internalization of the receptor, contributing to the reduction in sst2 expression and 125 I-Tyr 11 -SRIF binding. The fact that sst1, sst3 and sst4 protein levels were unaltered after A␤ infusion is consistent with this hypothesis, since none of these receptors seem to be regulated by GRK2.
Minocycline administration to A␤(25-35)-infused rats restored GRK2 levels to baseline values, concomitant with the normalization of sst2 expression and SRIF binding. GRK mRNA levels are altered in a number of pathologies associated with GPCR dysfunction (Gainetdinov et al., 2004) yet very little is known about the mechanisms governing GRK transcription. Protein kinase C (PKC) has been demonstrated to enhance GRK2 promoter activity in cardiovascular cells (Ramos-Ruiz et al., 2000) . A study of Nikodemova et al. (2006) suggests that minocycline inhibits PKC in microglial cells. Therefore it is feasible that minocycline could abrogate the rise in GRK2 expression induced by A␤(25-35) via PKC inhibition, thus restoring sst2 mRNA and protein levels to control values.
Finally, A␤(25-35) administration led to a decrease in SRIF-mediated inhibition of AC activity, with no changes in either basal or FK-stimulated AC activity. This suggests that the decreased sensitivity of AC to SRIF was not due to an alteration in the catalytic subunit of the enzyme. In addition, Gi␣1, Gi␣2 and Gi␣3 protein levels were unaltered by A␤(25-35) . Taken together, these findings suggest that the lower SRIF-mediated inhibition of AC activity is most probably due to the decrease in sst density. O'Neill et al. (1994) have shown a preservation of Gi-proteininhibited AC activity in the frontoparietal cortex of AD patients. In our study, minocycline administration to rats treated with either A␤(25-35) or vehicle did not alter basal or FK-stimulated AC activity. These results extend previous studies in vitro in which minocycline exerted no effect on cAMP formation in rat cerebral cortical slices (Mork and Geisler, 1993) . In the A␤(25-35)-treated group, however, minocycline restored the ability of SRIF to inhibit AC, most probably due to the normalization of sst2.
Given the potent amnesic properties reported for A␤(25-35) (Nitta et al., 1994) and the role of SRIF in cognitive processes (Dournaud et al., 1996) , the A␤(25-35)-induced reduction in sst density and sst2 expression might be involved in the impairment of cognitive function reported by several laboratories after A␤ administration. The fact that minocycline improves cognition in APP-transgenic mice suggests that this improvement might partly be accounted for by the protective effects of the drug on the SRIF signaling pathway. Our findings also suggest a possible link between sst2 and GRK2 in patients with AD. Future studies may shed new light on the potentially beneficial effects of minocycline in AD.
